ライフサイエンスコーパス: basiliximab

1 ong patients receiving ATG (42% vs. 11% with basiliximab).

2 of mycophenolate mofetil and induction with basiliximab.

3 o weeks later, she received a second dose of basiliximab.

4 iated by immunoglobulin (Ig) E antibodies to basiliximab.

5 al rates, and the safety and tolerability of basiliximab.

6 imus (0.2mg/kg/day delayed until Day 5) plus basiliximab.

7 urrence of dnDSA and ABMR when compared with basiliximab.

8 ents having received either Thymoglobulin or basiliximab.

9 -2 receptor (anti-CD25) monoclonal antibody, basiliximab.

10 ction immunosuppression was with intravenous basiliximab (10 mg on postoperative days 0 and 4).

11 atients was lower with alemtuzumab than with basiliximab (10% vs. 22%, P=0.003), but among high-risk

12 Two hundred twenty-nine patients (102 basiliximab, 127 controls) were analyzed, mean age 54 ye

13 uction, transitional era, 1994 to 2002, when basiliximab (1998), daclizumab (1998), and rabbit antith

14 y ACR was more frequent in SPKT induced with basiliximab (2-year 12.8% vs. 3.1%, P=0.04), but the inc

15 n = 17) or nondepleting, anti-CD25 antibody (basiliximab, 2 x 40 mg, n = 25) induction therapy, in co

16 Patients received either basiliximab (20 mg on day 0 and day 4 posttransplantatio

17 lantation (day 0) and on days 1 through 4 or basiliximab (20 mg, 137 patients) on days 0 and 4.

18 The dose of basiliximab-20-mg infusions on day 0 and day 4-was selec

19 tal of 260 kidney-only recipients were given basiliximab (232) or thymoglobulin (28) induction, and s

20 was not significantly different between the basiliximab (29%) and placebo (43%) groups (P=0.16).

21 ti-IL-2 receptor mAb) for induction therapy (basiliximab: 5 mg intravenously on days 0 and 4) plus lo

22 occurred significantly less frequently with basiliximab (54%) than placebo (73%) (P=0.046).

23 ast 1 dose of study medication (70 patients, basiliximab; 65 patients, ATG).

24 umab (one dose of 30 mg, in 164 patients) or basiliximab (a total of 40 mg over 4 days, in 171 patien

25 se III study was performed to assess whether basiliximab, a chimeric anti-interleukin-2 receptor mono

26 Basiliximab, a chimeric monoclonal antibody directed aga

27 ab, and 26% of those given the 20-mg dose of basiliximab achieved clinical remission (P = 1.00 vs pla

28 igher with ATG and alemtuzumab compared with basiliximab (adjusted subdistribution hazard ratio [aSHR

29 l-directed therapies including halofuginone, basiliximab, alemtuzumab, abatacept and rapamycin have b

30 survival was similar in both groups (2-year basiliximab/alemtuzumab 94.7%/91.2%), but death-censored

31 nt with daclizumab (alone or with steroids), basiliximab alone, or steroids alone.

32 antibody TS-1/22 in combination with either basiliximab (an IL-2Ralpha-specific mAb) and sirolimus (

33 rabbit antithymocyte polyclonal antibody or basiliximab, an interleukin-2 receptor monoclonal antibo

34 creatinine at 12 months was 141 mumol/L with basiliximab and 164 mumol/L with placebo (not significan

35 t and patient survivals were 88% and 98% for basiliximab and 88% and 96% for placebo (not significant

36 ection was 19% and 20%, respectively, in the basiliximab and ATG groups.

37 hic characteristics were similar between the basiliximab and ATG-treatment groups.

38 ion (6% vs. 6%; P=0.90) were similar between basiliximab and control groups, respectively.

39 val and renal function were compared between basiliximab and control groups.

40 plus standard-dose Tac; both groups received basiliximab and corticosteroids.

41 Basiliximab and cyclosporine had little effect on apopto

42 Basiliximab and daclizumab are potent and relatively saf

43 enal graft failure than nondepleting agents (basiliximab and daclizumab).

44 nd mycophenolate mofetil plus induction with basiliximab and LFA-1 blockade.

45 75mg/kg/day) immediately posttransplant plus basiliximab and MMF (without maintenance corticosteroids

46 re no immediate side effects associated with basiliximab and no evidence of cytomegalovirus infection

47 g induction agents has decreased in favor of basiliximab and no induction during the COVID-19 pandemi

48 no significant differences in safety between basiliximab and placebo in both diabetic and nondiabetic

49 Adverse events were similar in the basiliximab and placebo treatment groups.

50 lant induced with low-dose thymoglobulin and basiliximab and randomized to MMF (750 mg twice/day, n =

51 rATG recipients, but did not differ between basiliximab and rATG recipients.

52 , 163 days) compared to recipients receiving basiliximab and sirolimus alone (graft survival time 8,

53 CTLA4Ig plus 3A8, basiliximab and sirolimus was well tolerated and induced

54 llogeneic islet transplantation and received basiliximab and sirolimus with or without 2C10.

55 ays compared to 8 days in controls receiving basiliximab and sirolimus; p = 0.022).

56 included, 64.0% received ATG, 23.4% received basiliximab, and 12.6% received alemtuzumab.

57 lacebo, 29% of those given the 40-mg dose of basiliximab, and 26% of those given the 20-mg dose of ba

58 LD with rabbit antithymocyte globulin (ATG), basiliximab, and alemtuzumab inductions.

59 .2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids given only perioperativ

60 = 5) were treated with alefacept in place of basiliximab, and more intense LFA-1 blockade.

61 A prolonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive

62 2), patients received tacrolimus, steroids, basiliximab, and sirolimus.

63 -interleukin-2 receptor monoclonal antibody, basiliximab, and the rabbit antihuman thymocyte preparat

64 rofile of adverse events was similar between basiliximab- and ATG-treated patients, adverse events co

65 2) receptor (CD25) monoclonal antibody (mAb) basiliximab (anti-IL-2 receptor mAb) for induction thera

66 lls was associated with the presence of anti-basiliximab antibodies (odds ratio, 21; 95% confidence i

67 er in the alemtuzumab group (n=6 vs. n=14 in basiliximab arm) just reaching statistical significance

68 elease tacrolimus (0.15-0.175mg/kg/day) plus basiliximab; Arm 3: prolonged-release tacrolimus (0.2mg/

69 We investigated the efficacy and safety of basiliximab as a corticosteroid-sensitizing agent in pat

70 At 12 months, basiliximab as compared with placebo reduced the proport

71 e with the substitution of thymoglobulin for basiliximab as induction therapy for recipients at incre

72 recipients having received Thymoglobulin or basiliximab as induction therapy.

73 0) and the anti-interleukin (IL)-2R antibody basiliximab, as part of a phase 2 study.

74 ring rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induction in renal transplant recipien

75 antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab (BAS)/EVR (N = 102); BAS/MPS (N = 101).

76 matched controls induced with alemtuzumab or basiliximab (Bas)/low-dose rabbit anti-thymocyte globuli

77 It is not clear whether the efficacy of basiliximab (BSX) is different from that of Thymoglobuli

78 oglobulin (antithymocyte globulins [ATG]) or basiliximab (BSX) therapy.

79 ACR is better prevented by alemtuzumab than basiliximab, but no relevant difference is found in prev

80 Basiliximab combined with early initiation of cyclospori

81 All patients received basiliximab +/- corticosteroids.

82 CRT recipients received basiliximab, corticosteroids, mycophenolate mofetil (MMF

83 ompared with standard immunosuppression with basiliximab, corticosteroids, tacrolimus, and mycophenol

84 Immunosuppression comprised of basiliximab, cyclosporine, sirolimus, and steroid minimi

85 present, with most patients receiving rATG, basiliximab, daclizumab, or alemtuzumab (2003).

86 All patients received two 20-mg doses of basiliximab (days 0 and 4 after transplantation) followe

87 Sirolimus also delays the repopulation of basiliximab-depleted CD25 T cells compared with cyclospo

88 Basiliximab does not increase the effect of corticostero

89 In addition, basiliximab does not increase the incidence of adverse e

90 Our study shows that induction therapy with basiliximab enabled SDZ RAD blood levels to be significa

91 mab, tacrolimus, everolimus, and prednisone (basiliximab/EVR, n = 102); or basiliximab, tacrolimus, m

92 High immune responders treated with basiliximab expressed a higher mean serum creatinine lev

93 ted a novel immunosuppressive combination of basiliximab for induction and of RAD and FTY720 for main

94 Immunosuppression consisted of basiliximab for induction therapy and tacrolimus, mycoph

95 A strategy combining sirolimus with basiliximab for low-immunologic risk recipients and thym

96 ntly lower in the alemtuzumab group than the basiliximab group (0.12 +/- 0.29 vs 0.74 +/- 0.67; P < 0

97 er rejection was significantly higher in the basiliximab group (P < 0.0001).

98 hymoglobulin group and 28 (73%) of 38 in the basiliximab group (P=0.77).

99 Five (2.9%) deaths in the basiliximab group and seven (4.0%) in the placebo group

100 The antithymocyte globulin group and the basiliximab group had similar incidences of graft loss (

101 ymocyte globulin group, as compared with the basiliximab group, had lower incidences of acute rejecti

102 In the basiliximab group, the predominant cause of kidney loss

103 odialysis at LT (29% vs. 6%; P<0.001) in the basiliximab group.

104 for alemtuzumab group and 53+/-21 mL/min for basiliximab group; P=0.42).

105 Six subjects who received basiliximab had serious adverse events (6.1%) compared w

106 Basiliximab improved the maximal proliferation count in

107 Basiliximab in combination with a tacrolimus-based immun

108 tudy, we assessed the efficacy and safety of basiliximab in combination with a tacrolimus-based regim

109 short courses of antithymocyte globulin and basiliximab in patients at high risk for acute rejection

110 rapy changed during the study timeframe from basiliximab in the NG group to alemtuzumab in the no NG

111 In subjects given basiliximab, incomplete saturation of CD25 (<50%) on per

112 dermal administration of a 1:100 dilution of basiliximab induced a 10 x 10-mm flare.

113 0 y (hazard ratio [HR], 2.57; P < 0.001) and basiliximab induction (HR, 1.69; P = 0.018) were indepen

114 significantly increases in association with basiliximab induction and decreases with MMF maintenance

115 We compared LT outcomes using basiliximab induction and delayed CNI initiation to cont

116 ransplant recipients, CMV IgG + , were given basiliximab induction and maintained on steroid/mycophen

117 Adding basiliximab induction and maintenance tacrolimus to the

118 Immunosuppression was basiliximab induction and maintenance was a calcineurin

119 irolimus (n=31) or cyclosporine (n=30) after basiliximab induction and mycophenolate mofetil (MMF) wi

120 Calcineurin inhibitor drug avoidance with basiliximab induction and sirolimus provides comparable

121 Thymoglobulin and basiliximab induction and tacrolimus-based immunosuppres

122 no major differences detected compared with basiliximab induction and tacrolimus/MMF maintenance at

123 een adult patients were randomized to either basiliximab induction followed by tacrolimus and MMF mai

124 ve steroid-free CsA therapy, suggesting that basiliximab induction may be useful as a strategy in oth

125 the same standard immunosuppression, except basiliximab induction replaced ATDC therapy and mycophen

126 Basiliximab induction resulted in 30-day and 1-year pati

127 in the presence of everolimus, steroids and basiliximab induction results in good efficacy in de nov

128 Basiliximab induction therapy did not influence CD4 and

129 Basiliximab induction was associated with improved graft

130 d immunosuppression mirrored the RGT, except basiliximab induction was substituted with CBMPs and myc

131 ronchial necrosis >2 cm from anastomosis and basiliximab induction were also independent risk factors

132 nduction with tacrolimus monotherapy against basiliximab induction with tacrolimus and mycophenolate

133 (no induction) compared with CRT recipients (basiliximab induction), despite similar chronic immunosu

134 islets using the CD40-specific antibody 3A8, basiliximab induction, and sirolimus with or without CTL

135 All subjects received basiliximab induction, mycophenolate mofetil, and cortic

136 All patients received basiliximab induction, mycophenolic acid and corticoster

137 /mL), acute rejection (time-dependent), age, basiliximab induction, sex, donor age, human leukocyte a

138 Immunosuppression included basiliximab induction, tacrolimus, and prednisone (+/- s

139 levels of CsA-ME because of the addition of basiliximab induction.

140 All patients received basiliximab induction.

141 immunosuppressive treatment with or without basiliximab induction.

142 ceived antithymocyte globulin and 2 received basiliximab induction.

143 therapy versus those treated with anti-CD25 (Basiliximab) induction therapy and maintenance immunosup

144 BACKGROUND & AIMS: Basiliximab is a chimeric monoclonal antibody that binds

145 regimen and comparable effectiveness to ATG, basiliximab is an attractive choice for the prevention o

146 Basiliximab is associated with a significant reduction i

147 th an interleukin-2 receptor antagonist, and basiliximab is the most used agent.

148 After basiliximab levels fell below the minimum therapeutic le

149 ients received prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intrao

150 Basiliximab, mycophenolate mofetil, and corticosteroids

151 All patients received induction therapy with basiliximab, mycophenolate mofetil, and corticosteroids.

152 ed to belatacept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

153 , tacrolimus, mycophenolate, and prednisone (basiliximab/mycophenolate, n = 101).

154 Sixty patients (Thymoglobulin n=22 and basiliximab n=38) were included.

155 e early posttransplant period and received a basiliximab (n = 2) or antithymocite globulin-based indu

156 nal allograft recipients who received either basiliximab (n=115) or thymoglobulin (n=30) in combinati

157 sion: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29) and were followed up for 36 months.

158 th alemtuzumab (n=97) and those induced with basiliximab (n=39).

159 calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppre

160 plantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclospo

161 lant recipients were randomized and received basiliximab (n=52) or placebo (n=56) to assess whether b

162 atient received induction therapy with 20 mg basiliximab on days 0 and 4, and maintenance therapy wit

163 Following either basiliximab or alemtuzumab induction patients with lower

164 (C1H); (3) IL2-receptor antagonists (IL2-RA; basiliximab or daclizumab), and (4) No antibody inductio

165 an either low immune responders treated with basiliximab or high immune responders treated with thymo

166 s superiority of thymoglobulin compared with basiliximab or no antibody induction therapy for 6-month

167 Patients receiving basiliximab or no induction therapy served as controls.

168 e use of lymphocyte-depleting agents (versus basiliximab or no induction) and maintenance steroids (v

169 ose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidat

170 were given 20 mg (n = 46) or 40 mg (n = 52) basiliximab or placebo (n = 51) at weeks 0, 2, and 4.

171 ed, equally sized groups treated with either basiliximab or placebo.

172 emtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin).

173 in 2001 to 2005 managed with thymoglobulin, basiliximab, or no antibody induction and discharge main

174 Compared with placebo, a higher fraction of basiliximab patients produced urine in the operating roo

175 ndicates that, compared with alemtuzumab and basiliximab, rATG associates with lower risk of adverse

176 tithymocyte globulin (rATG) (5330 pairs) and basiliximab-rATG (9378 pairs) recipients.

177 Compared with rATG recipients, basiliximab recipients had higher risk of death (HR, 1.0

178 ually divided into the two treatment groups, basiliximab reduced the proportion of patients who exper

179 of antithymocyte globulin, as compared with basiliximab, reduced the incidence and severity of acute

180 b (n=52) or placebo (n=56) to assess whether basiliximab reduces the need for addition of steroids or

181 sk than CRT recipients who were administered basiliximab (relative risk: 3.6, P<0.002).

182 ion included rabbit anti-thymocyte globulin, basiliximab, rituximab, eculizumab, tofacitinib, tacroli

183 se findings demonstrate that the addition of basiliximab significantly reduces the need to modify the

184 Basiliximab (Simulect), a chimeric anti-interleukin-2 re

185 Basiliximab (Simulect), a high-affinity chimeric, monocl

186 interleukin-2 receptor antibodies (IL-2RAs): basiliximab (Simulect; Novartis, Basel, Switzerland) and

187 tokine-induced JAK/STAT5 activation, whereas basiliximab suppresses IL-2-stimulated activation only.

188 l intent-to-treat population (143 tacrolimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofe

189 (rabbit antithymocyte globulin/EVR, n = 85); basiliximab, tacrolimus, everolimus, and prednisone (bas

190 Immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil, and cort

191 nd prednisone (basiliximab/EVR, n = 102); or basiliximab, tacrolimus, mycophenolate, and prednisone (

192 rt of 569 patients administered standardized basiliximab-tacrolimus-mycophenolate-corticosteroid immu

193 ial (RGT) was a standard-of-care group given basiliximab, tapered steroids, mycophenolate mofetil, an

194 Prophylactic basiliximab therapy is well tolerated, has an adverse ev

195 Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on

196 Basiliximab therapy showed an excellent safety profile,

197 sponse to IL-2 decreased after both rATG and basiliximab therapy.

198 signed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy fo

199 We previously reported that the use of basiliximab together with sirolimus permits a window of

200 Graft losses occurred in 9 (5.2%) basiliximab-treated and 12 (6.9%) placebo-treated patien

201 Basiliximab-treated high immune responders exhibited a h

202 f acute rejection episodes (26%) than either basiliximab-treated low immune responders (10%, P=0.04)

203 During the first 12 months, 94 (54%) basiliximab-treated patients experienced serious adverse

204 acity for CMV-specific CMI was only found in basiliximab-treated patients for both preemptive and pro

205 During the trial, 33% of basiliximab-treated patients received oral steroids at s

206 t, risk reduction among thymoglobulin versus basiliximab-treated patients was of larger magnitude but

207 By the end of the study, 25% of basiliximab-treated patients were receiving maintenance

208 differences in expression between rATG- and basiliximab-treated patients.

209 Conventional immunosuppressive or basiliximab treatment cannot control the persistence of

210 In contrast, CNI/basiliximab treatment did not affect IL-7-activated or I

211 patients, 7 days after starting tofacitinib/basiliximab treatment, cytokine-induced P-STAT5 was inhi

212 intained in diabetic recipients treated with basiliximab versus placebo (96% vs. 86%; P=0.022).

213 e randomized to receive either daclizumab or basiliximab versus RATG for induction in combination wit

214 ncidence of AMR was similar (2-year 18% with basiliximab vs. 13.8% with alemtuzumab, P=NS).

215 acute rejection episodes by 28%: 61 (35.3%) basiliximab vs. 85 (49.1%) placebo (P=0.009).

216 Basiliximab was generally well tolerated.

217 In multivariable logistic regression, basiliximab was not significantly associated with 30-day

218 py with alemtuzumab or IL-2RA (daclizumab or basiliximab) was used.

219 le endpoint with thymoglobulin compared with basiliximab when steroids were present, with approximate

220 patients received everolimus, steroids, and basiliximab with low or standard tacrolimus exposure.

221 ducted to compare the efficacy and safety of basiliximab with placebo in renal transplant recipients

222 changed our primary induction protocol from basiliximab with standard maintenance immunosuppression

223 ne, rATG with steroids, rATG alone, and then basiliximab with steroids.

224 ore </=2, no subscore >1) for patients given basiliximab with the rate for patients given placebo.

225 e treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introduction of sirolimus in p

226 t a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipat